Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.
The nephrotoxic effect of COX-2 selective inhibitors has not yet been established. We report a case of reversible acute renal failure due to acute tubulointerstitial nephritis, confirmed by histology of a renal biopsy sample, associated with taking rofecoxib, a selective cyclo-oxygenase-2 (COX-2) inhibitor.
Rocha
J L
JL
Fernández-Alonso
J
J
D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000473:pathology; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007677:Kidney Function Tests; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology; D007684:Kidney Tubules / Q000187:drug effects / Q000473:pathology; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects*; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000473:pathology; D010003:Osteoarthritis / Q000188:drug therapy*; D013450:Sulfones
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib